Kailera Therapeutics Inc

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. The company is headquartered in Waltham, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2026-04-17. The firm is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The firm is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.